Increasing TRAIL levels may be an attractive therapeutic strategy, to reduce features of diabetes, as well as liver and vascular injury, so commonly observed in individuals with NAFLD. The gene discussed is TNFSF10; the disease is metabolic dysfunction-associated steatotic liver disease.